Browsing by Author "Tambatamba B"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Field performance evaluation of dual rapid HIV and syphilis tests in three antenatal care clinics in Zambia.
    (2019-Mar) Kasaro MP; Bosomprah S; Taylor MM; Sindano N; Phiri C; Tambatamba B; Malumo S; Freeman B; Chibwe B; Laverty M; Owiredu MN; Newman L; Sikazwe I; 4 Division of STD Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.; 7 World Health Organization, Intercountry Support Team for East and Southern Africa, Harare, Zimbabwe.; 1 Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; 6 World Health Organization Country Office, Lusaka, Zambia.; 5 Ministry of Community Development, Mother and Child Health, Lusaka, Zambia.; 8 Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Phnom Penh, Cambodia.; 2 Department of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.; 3 Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    This cross-sectional study of 3212 pregnant women assessed the field performance, acceptability, and feasibility of two dual HIV/syphilis rapid diagnostic tests, the Chembio DPP HIV-syphilis Assay and the SD Bioline HIV/syphilis Duo in antenatal clinics. Sensitivity and specificity for HIV and syphilis were calculated compared to the rapid Determine HIV-1/2 with Uni-Gold to confirm positive results for HIV and the Treponema pallidum particle agglutination assay for syphilis. RPR titers ≥1:4 were used to define active syphilis detection. Acceptability and feasibility were assessed using self-reported questionnaires. For Chembio, the HIV sensitivity was 90.6% (95%CI = 87.4, 93.0) and specificity was 97.2% (95%CI = 96.2, 97.8); syphilis sensitivity was 68.6% (95%CI = 61.9, 74.6) and specificity was 98.5% (95%CI = 97.8, 98.9). For SD Bioline, HIV sensitivity was 89.4% (95%CI = 86.1, 92.0) and specificity was 96.3% (95%CI = 95.3, 97.1); syphilis sensitivity was 66.2% (95%CI = 59.4, 72.4) and specificity was 97.2% (95%CI = 96.4, 97.9). Using the reference for active syphilis, syphilis sensitivity was 84.7% (95%CI = 76.1, 90.6) for Chembio and 81.6% (95%CI = 72.7, 88.1) for SD Bioline. Both rapid diagnostic tests were assessed as highly acceptable and feasible. In a field setting, the performance of both rapid diagnostic tests was comparable to other published field evaluations and each was rated highly acceptable and feasible. These findings can be used to guide further research and proposed scale up in antenatal clinic settings.
  • Thumbnail Image
    Item
    Interrupted time-series analysis of active case-finding for tuberculosis during the COVID-19 pandemic, Zambia.
    (2022-Mar-01) Lungu PS; Kerkhoff AD; Muyoyeta M; Kasapo CC; Nyangu S; Kagujje M; Chimzizi R; Nyimbili S; Khunga M; Kasese-Chanda N; Musonda V; Tambatamba B; Kombe CM; Sakulanda C; Sampa K; Silumesii A; Malama K; National Tuberculosis and Leprosy Control Programme, Ministry of Health, Ndeke House, Haile-Selaise Road, PO Box 30205, Lusaka, Zambia.; United States Agency for International Development, Lusaka, Zambia.; Eradicate Tuberculosis Project, United States Agency for International Development, Lusaka, Zambia.; Ministry of Health, Lusaka, Zambia.; Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, United States of America.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    OBJECTIVE: To evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic and the subsequent implementation of tuberculosis response measures on tuberculosis notifications in Zambia. METHODS: We used an interrupted time-series design to compare monthly tuberculosis notifications in Zambia before the pandemic (January 2019 to February 2020), after implementation of national pandemic mitigation measures (April 2020 to June 2020) and after response measures to improve tuberculosis detection (August 2020 to September 2021). The tuberculosis response included enhanced data surveillance, facility-based active case-finding and activities to generate demand for services. We used nationally aggregated, facility-level tuberculosis notification data for the analysis. FINDINGS: Pre-pandemic tuberculosis case notifications rose steadily from 2890 in January 2019 to 3337 in February 2020. After the start of the pandemic and mitigation measures, there was a -22% (95% confidence interval, CI: -24 to -19) immediate decline in notifications in April 2020. Larger immediate declines in notifications were seen among human immunodeficiency virus (HIV)-positive compared with HIV-negative individuals (-36%; 95% CI: -38 to -35; versus -12%; 95% CI: -17 to -6). Following roll-out of tuberculosis response measures in July 2020, notifications immediately increased by 45% (95% CI: 38 to 51) nationally and across all subgroups and provinces. The trend in notifications remained stable through September 2021, with similar numbers to the predicted number had the pandemic not occurred. CONCLUSION: Implementation of a coordinated public health response including active tuberculosis case-finding was associated with reversal of the adverse impact of the pandemic and mitigation measures. The gains were sustained throughout subsequent waves of the pandemic.